A double-blind, placebo-controlled multicentre trial of memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies.

Trial Profile

A double-blind, placebo-controlled multicentre trial of memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2015

At a glance

  • Drugs Memantine (Primary)
  • Indications Dementia; Lewy body disease; Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms MEMPDD
  • Most Recent Events

    • 25 Apr 2015 Pooled analysis results of this trial and other two 24-Week , placebo-controlled trials presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 17 Jul 2013 Secondary endpoint (Clinical Dementia Rating) results presented at the 2013 Alzheimer's Association International Conference .
    • 26 Jul 2010 Additional lead trial centre Helse Stavanger HF and trial investigator (Aarsland D) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top